<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib0190">
 <label>38</label>
 <element-citation publication-type="journal" id="sbref0190">
  <person-group person-group-type="author">
   <name>
    <surname>Gabay</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Fautrel</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Rech</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Spertini</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Feist</surname>
    <given-names>E.</given-names>
   </name>
  </person-group>
  <article-title>Open-label, multicentre, dose- escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Stillâ€™s disease</article-title>
  <source>Ann Rheum Dis.</source>
  <volume>77</volume>
  <issue>6</issue>
  <year>2018</year>
  <fpage>840</fpage>
  <lpage>847</lpage>
  <pub-id pub-id-type="doi">10.1136/annrheumdis-2017-212608</pub-id>
  <pub-id pub-id-type="pmid">29472362</pub-id>
 </element-citation>
</ref>
